The Homolog Argument: THCP and THC-Octyl Under the Analogue Act

This page is analysis and advocacy — it is not legal advice

Read this before you read anything else on the page. What follows is a research and policy brief. It is written to be used by regulators, legislators, counsel and industry researchers as an argument, and the argument is stated at full strength because a hedged brief is useless to the people who need it. It is not a legal opinion, it is not a clearance, and it is not advice to you. Three things make that more than a formality. First, cannabinoid law varies enormously by state: a compound that is lawful under federal law can be a felony in the jurisdiction where you live, ship, store or sell, and state analogue statutes, total-intoxicant caps and compound-by-name bans operate independently of the federal scheme described here. Second, this area of law is changing quickly — the federal definition of hemp itself was rewritten in late 2025 with a delayed effective date, state legislatures have moved in both directions in every recent session, and agency positions have shifted. Anything written here can be overtaken by an amendment, a rule, or a decision. Third, an argument that a substance is not a controlled substance analogue is a defence, not a permission: it is something a defendant says after being charged, and the fact that it is a good argument does not mean nobody will be charged. Do not make a business decision, a product decision or a personal decision on the basis of this page. Get your own lawyer, licensed in your own jurisdiction, and give them the actual facts. This page makes the strongest available argument that these compounds are not analogues. That argument is unlitigated. Treat it as a brief to be tested, not as a conclusion you can rely on.

• Not legal advice, and no lawyer-client relationship arises from reading it.
• Federal lawfulness does not imply state lawfulness — check your own state, and the states you ship to.
• The law described here is in motion; a delayed federal effective date sits in the middle of it.
• A strong non-analogue argument is a defence to a charge, not immunity from one.
• Nothing here is medical advice either, and nothing here is an endorsement of using any compound.

The compounds contested in vitro

Delta-9-THC carries a five-carbon (pentyl) alkyl chain on the resorcinol ring. The homolog series varies that chain and nothing else. Delta-9-tetrahydrocannabiphorol (THCP) carries a seven-carbon heptyl chain and was isolated from a medicinal cannabis variety and characterised by Citti and colleagues in 2019, who reported a CB1 binding affinity of Ki about 1.2 nM against roughly 40 nM for delta-9-THC, together with greater in-vivo cannabimimetic activity in mice. The same Italian group isolated the butyl (C4) homolog delta-9-THCB and the hexyl (C6) homologs, so the series is an established feature of the plant's chemistry rather than a single curiosity. The compound sold as THCJD is described commercially as the octyl (C8) homolog, delta-9-THC-C8 or tetrahydrocannabioctyl, and is also equated in tertiary sources with JWH-138, a classical-cannabinoid member of the JWH numbering series described as delta-8-THC-octyl with a reported CB1 Ki near 8.5 nM. The naming around the C8 material is genuinely messy and the page treats it carefully: THC-octyl is sometimes written THC-O, which collides with the wholly different acetate ester THC-O-acetate, and the delta-8 and delta-9 C8 isomers are not the same compound.

Contested — caveat. The THCP affinity figure is from a single 2019 paper and has not been independently replicated in the form cited. The octyl row rests on tertiary sources; no primary isolation or binding paper for the C8 homolog was located in this pass, and the identification of commercial "THCJD" with JWH-138 is not verified. Single-paper Ki values should never be quoted as settled pharmacology.

Sources: Citti C 2019 · Linciano P 2019 · Linciano P 2020 · Citti C 2024 · Tertiary reference compilations 2025*

Prong (i), structure: side-chain length is not an incidental variation

The structural argument is the strongest limb and it is not a lawyer's argument — it comes straight out of the structure-activity literature. Extending the side chain from pentyl to heptyl adds two carbons to a five-carbon chain, a 40 percent increase; to octyl, three carbons, 60 percent. The response of the point that counters it is obvious: two carbons is a small change to a molecule of twenty-one. The answer is that in this particular structural class the side chain is not a peripheral substituent, it is the principal determinant of activity, and that has been known since the 1940s. Roger Adams's analog series at Illinois systematically varied the side chain and established that activity tracked it; the branched dimethylheptyl chain, discovered in that programme, raised potency by orders of magnitude over the natural pentyl compound. Sixty years of cannabinoid medicinal chemistry has rested on the same fact, and the modern isolation of the butyl, hexyl and heptyl homologs from the plant confirmed it from the natural-products side: potency rises with chain length up to about seven or eight carbons and then falls away. So the side chain is the structural element the pharmacology is most sensitive to. A statute that asks whether chemical structures are substantially similar, applied to a class where one variable dominates the pharmacology, is asking about precisely that variable — and a change in precisely that variable is the least incidental change available in the class. That is the argument, and it is a good one. Its weakness is that it can be inverted: if side-chain length is the dominant variable and the scaffold is otherwise identical, an expert for the government will say the molecules are the same compound with a different chain, and a factfinder may agree. The argument establishes that the difference is pharmacologically meaningful. Whether "pharmacologically meaningful" is what the statute means by "not substantially similar" is the unresolved question, and it is unresolved because, as the previous page sets out, Congress never said.

• Pentyl to heptyl: a 40 percent increase in side-chain carbon count. Pentyl to octyl: 60 percent.
• Side-chain length is the dominant structure-activity variable in the classical cannabinoid series, established in the Adams analog programme of the 1940s.
• The dimethylheptyl chain from that programme raised potency by orders of magnitude — the same structural lever, pushed further.
• The natural homolog series isolated from 2019 onward confirms the same relationship in plant-derived compounds.
• Therefore: a change in side-chain length is the change in this class that is least plausibly described as incidental.

Sources: Adams R 1941 · Adams R 1949 · Citti C 2019 · Linciano P 2019 · Linciano P 2020 · United States Code 1986

The sharpest version: any standard that captures THCP captures CBD a fortiori

This is the argument to lead with, because it does not require a factfinder to weigh degrees of similarity — it forces a consistency problem. Cannabidiol and delta-9-THC have the same molecular formula, C21H30O2. Same molecular weight. Same carbon count. Same pentyl side chain. Same resorcinol-plus-terpenoid scaffold and the same biosynthetic parent, cannabigerolic acid, differing only in which synthase closes the structure. They are structural isomers of one another, and the entire difference between them is whether one ring is closed: the pyran ring of THC against the open, free-phenol form of CBD. Indeed the two are interconvertible by a single-step acid-catalysed rearrangement, a transformation documented by Adams in 1940 and 1941, by Gaoni and Mechoulam in 1966, patented by Webster, Sarna and Mechoulam in 2008, reviewed by Bloemendal and colleagues in 2020 and examined in a forensic context by Kiselak and colleagues in 2020 — the conversion is well documented in the literature and chemically undemanding, which is a policy fact and is cited here for that purpose only. Now compare THCP: it differs from delta-9-THC in molecular formula, in molecular weight and in carbon count, while sharing the closed pyran ring and the double-bond position. By any ordinary structural measure — formula identity, atom count, scaffold, isomerism, single-step interconvertibility — CBD is closer to delta-9-THC than THCP is. And CBD is lawful federally: it is a cannabinoid within the 2018 definition of hemp, it is an approved active pharmaceutical ingredient, and it has never been treated as an analogue of delta-9-THC by anyone. It follows that no structural-similarity standard can capture THCP without capturing CBD a fortiori. A standard that reaches the one and not the other is not a standard; it is a result looking for a rationale. The government's available answer is to shift to prong (ii) and say the distinction is pharmacological rather than structural — CBD is not a CB1 orthosteric agonist and THCP is. That answer concedes the structural point, which is the point of making the argument this way.

Sources: United States Code 2018 · Adams R 1940 · Adams R 1941 · Gaoni Y 1966 · Webster GRB 2008 · Bloemendal VRLJ 2020 · Kiselak TD 2020 · Gagne SJ 2012 · Citti C 2019

Prong (ii), effects: the weakest limb, and it should be conceded as such contested anecdotal

The operator's earlier version of this argument treats the effects prong as a strength: greater potency, on this view, means a different pharmacological profile, and different means not substantially similar. That framing will not survive a reading of the statute, and a brief that leans on it loses credibility on the rest. The text of prong (ii) is "substantially similar to or greater than" — greater effect is expressly inside the prong. An argument that a compound is too potent to be an analogue is arguing against the words Congress used. The defensible version of the point is narrower and should be stated as narrow. It is that potency and profile are different things: a 30-fold difference in receptor affinity is a quantitative statement, and the prong asks about a stimulant, depressant or hallucinogenic effect on the central nervous system. There is a genuine argument that a compound with markedly different efficacy at CB1, a different dose-response curve, a different duration and a different qualitative character of effect is not producing the same effect more strongly but a different effect — and users of the C8 material do describe it in qualitatively different, more psychedelic terms, which is anecdotal evidence and no more than that. Even so, a court is entitled to read prong (ii) as satisfied by cannabimimetic activity at any potency, and that is the likely reading. Assess this limb honestly: prong (ii) probably goes against the position. The argument has to be won on prong (i), and on prong (iii) where the facts support it.

Contested — caveat. This section deliberately argues against the operator's earlier framing. Greater potency is inside the text of prong (ii). Reports of qualitatively different subjective effects for the C8 material are anecdotal and are not evidence of a different pharmacological class.

Sources: United States Code 1986 · Citti C 2019 · Tertiary reference compilations 2025*

Prong (ii) revisited: efficacy class is a stronger argument than potency, and it cuts both ways contested in vitro

There is a version of the prong (ii) argument that is stronger than the potency-multiplier framing just conceded, and it rests on primary pharmacology rather than on a Ki number. Martin and colleagues (1999) worked through a systematic series of THC side-chain variants and reported that the side chain does not simply turn up or down one axis of the same effect — it changes what kind of effect the molecule produces at CB1. The paper's own title states the finding: manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. Depending on the side chain, the resulting compound can be a full agonist, a partial agonist like Δ9-THC itself, or an outright antagonist that blocks rather than mimics cannabimimetic signalling at the receptor. That is a different structural lever from the pentyl-to-heptyl-to-octyl lengthening this page has otherwise been arguing about, but it establishes the same underlying point from primary data: the side chain is a pharmacophore determinant, not a dial that only turns one direction. The clean illustration is Δ9-tetrahydrocannabivarin (THCV), the propyl homolog three carbons shorter than THC's pentyl chain, which later work confirmed behaves as a competitive CB1 and CB2 antagonist rather than an agonist of any strength. The potency-multiplier argument (a homolog binds CB1 some multiple more tightly than THC) concedes the qualitative pharmacology and disputes only the degree, which is exactly why the prior section could not save it: prong (ii)'s own text reaches an effect "substantially similar to or greater than" the scheduled substance, so a bigger number argues itself into the prong rather than out of it. The efficacy-class point does not make that concession. If the homologous series produced by varying the THC side chain spans full agonists, partial agonists and antagonists — molecules that act on the same receptor in opposite functional directions — then structural membership in the series cannot by itself support an inference about what a given homolog's effect is, let alone that the effect is substantially similar to or greater than THC's. The effect has to be established compound by compound, from its own binding and functional data, not read off the scaffold or the chain length. Stated honestly, this is not a one-sided gift to the non-analogue position, and it should not be oversold as one. A homolog independently shown to be a full agonist with materially higher CB1 affinity than THC — the profile reported for THCP — sits squarely inside prong (ii) on its own facts, and the efficacy-class point does nothing to rescue that compound. What it defeats is the shortcut of inferring prong (ii) status from chain length or scaffold membership alone, in either direction: a prosecutor cannot point at the homologous series and assume agonism follows from structure, and a defendant cannot point at a longer chain and assume the only thing that changed is potency. Both sides need the actual pharmacology on the specific compound, and Martin 1999 is the primary source establishing that this series does not have one uniform answer to supply.

Contested — caveat. This argument is available to either side of a prong (ii) dispute and should not be presented as settling the question for THCP or THC-octyl specifically — it defeats the inference from scaffold to effect, not the effect itself where that effect has been independently measured.

Sources: Martin BR 1999 · United States Code 1986 · Citti C 2019

Prong (iii), representation, and the knowledge element

Prong (iii) is the limb where the commercial facts do real work, and it is worth separating the two things going on. As an element, prong (iii) asks what the particular person represented or intended. The homologs are sold under their own systematic chemical names — tetrahydrocannabiphorol, THCP, THC-octyl — on labelled products, usually with a certificate of analysis identifying the compound by name and quantity. They are not sold as THC, and they are not sold as marijuana. That is the opposite of the fact pattern the Act was written for and the one the K2 and Spice prosecutions presented, where the products were marketed as legal weed or as herbal incense not for human consumption, with the active compound undisclosed, mislabelled or absent from the label altogether. Hodge is the doctrinal anchor on the other side of this: representation alone did not make wax and flour an analogue, so prong (iii) is not a free-standing route to liability, and its absence therefore matters for a compound whose prong (i) case is contested. The second thing is scienter. After McFadden the government must prove either that the defendant knew he was dealing with a substance regulated under the Act, or that he knew the specific features that make it an analogue. A seller who names the compound accurately, tests it, labels the quantity, invoices it and pays tax on it is not thereby safe — knowledge of regulated status can be proved circumstantially and a good-faith belief in lawfulness is not a defence to the first route. But the evidentiary position is materially different from concealment, and concealment is what the reported analogue convictions tend to feature.

• Sold under systematic chemical names, not as THC or marijuana.
• Certificates of analysis identify the compound and its quantity — the opposite of an undisclosed active.
• Contrast the K2/Spice pattern: marketed as legal weed, actives undisclosed or mislabelled.
• Hodge: representation cannot supply the structural element, so its absence cuts the other way.
• McFadden: the government must prove knowledge of regulated status or of the analogue-making features.

Sources: United States Code 1986 · United States Court of Appeals for the Third Circuit 2003 · Supreme Court of the United States 2015 · Andrews R 2022

Phytocannabinoid versus cannabimimetic: a cousin, not a stranger in a similar outfit contested

The distinction that should carry the most weight with a chemically literate factfinder is between a homolog of a plant cannabinoid and a synthetic cannabimimetic, because the two are not the same kind of thing at all. The classical cannabinoid scaffold is a resorcinol joined to a terpenoid unit, and it is built in the plant by a single biosynthetic route: a polyketide, olivetolic acid, formed by the olivetolic acid cyclase pathway characterised by Gagne and colleagues in 2012, prenylated with geranyl pyrophosphate to cannabigerolic acid, then closed by one of the synthases to the acidic forms of THC, CBD or CBC. Vary the polyketide starter and the same machinery yields the same scaffold with a different side chain — which is exactly what the butyl, hexyl and heptyl homologs are, and why they occur in the plant at all. THCP and the octyl homolog retain that scaffold, retain the pyran closure, and share that biosynthetic origin. The JWH series is a different object. Those compounds — the naphthoylindoles such as JWH-018 and JWH-073, the phenylacetylindoles, the benzoylindoles, and the later indazole, oxizid and related generations documented by Andrews and colleagues — are built on an indole or indazole core with an acyl group, have no resorcinol, no terpenoid unit and no pyran ring, do not occur in nature, and were made in a receptor-pharmacology programme. They bind CB1 because a pharmacophore can be reached from more than one scaffold, and many of them are full agonists where THC is a partial agonist, which is a substantial part of why their toxicology is so much worse. The analogy is exact: a homolog is a cousin, and a cannabimimetic on an unrelated scaffold is a stranger in a similar outfit. One honest complication belongs here rather than in a footnote. The JWH numbering series is not exclusively indole-based; it includes classical cannabinoids, and the compound numbered JWH-138 is described in tertiary sources as delta-8-THC-octyl, that is, as a classical cannabinoid with an octyl chain. If that is right, then a compound in the JWH series and the compound marketed as THCJD are the same or nearly the same substance, and "it has a JWH number" tells you nothing about scaffold. That does not weaken the phytocannabinoid-versus-cannabimimetic distinction, which is about molecular architecture rather than about who made a compound or how it was numbered. It does mean the distinction has to be argued on architecture and not on the label.

Contested — caveat. The JWH-138 identification with THC-octyl rests on tertiary compilations and was not confirmed against a primary source in this pass. The architectural contrast in the table is well supported; the nomenclature point is flagged as unverified.

Sources: Gagne SJ 2012 · Radwan MM 2021 · ElSohly MA 2005 · Citti C 2019 · Linciano P 2019 · Andrews R 2022 · Huffman JW 2005* · Tertiary reference compilations 2025*

The historical-precedent argument, and the gap in it contested historical / ethnographic

The operator's brief makes a strong claim: that the octyl compound was identified in the scientific literature as early as 1941, decades before modern scheduling, so it cannot be characterised as a designer compound created to evade prohibition. The argument is worth making, because "designer drug" is doing real rhetorical work in this field and a compound described in a 1940s academic series is not one. But the claim as stated does not survive verification unchanged, and the honest version is narrower. What can be supported is that Roger Adams's analog programme at Illinois systematically varied the side chain through the 1940s and included long-chain and octyl members, and that a delta-3/delta-6a(10a) octyl isomer is reported in tertiary sources as having been synthesised in 1941, with a hydrogenated octyl analog studied around 1942. Three qualifications follow. That work was synthetic, not an isolation from the plant — so it establishes that the octyl scaffold has been known to chemistry since the 1940s, not that it was found in cannabis then. The 1941 isomer reported is a delta-3/delta-6a(10a) compound, which is a different isomer from the delta-8 or delta-9 C8 material sold commercially today. And the specific primary citation was not located in this pass; the date comes through tertiary compilations. The defensible form of the argument is therefore: the octyl homolog of the classical cannabinoid scaffold has been part of the published chemical literature since the Adams analog series of the 1940s, and long-chain homologs of the natural cannabinoids are not a recent invention of the intoxicant market. Any stronger claim — a 1941 identification in the plant, or a 1941 description of the specific compound now sold as THCJD — is not supported by anything verified here, and an argument that rests on an unverified citation is worse than one that admits the gap. If this brief is to be used, the underlying Adams papers should be pulled and the claim restated against them.

Contested — caveat. FLAGGED AS UNVERIFIED. The "identified as early as 1941" claim could not be confirmed against a primary source. What is verified: the Adams analog series exists and varied the side chain in this period. What is not: a 1941 primary citation for the octyl compound, the identity of that 1941 isomer with commercial THCJD, and any 1941 isolation from plant material. Do not use the 1941 date in a filing without pulling the paper.

Sources: Adams R 1941 · Adams R 1949 · Adams R 1940 · Tertiary reference compilations 2025*

Hemp Industries Association v. DEA, and the tryptophan analogy contested

Two supporting arguments come from outside the Analogue Act and are worth keeping in the brief, with their limits marked. The first is Hemp Industries Association v. DEA, 357 F.3d 1012 (9th Cir. 2004), which held that the DEA could not by interpretive rule reach naturally occurring cannabinoids in non-psychoactive hemp that Congress had not scheduled, and which reasoned that the schedule I tetrahydrocannabinols entry was aimed at the synthetic article while the natural plant was addressed by the marijuana provisions. Its transferable proposition is procedural — an agency cannot expand a schedule by interpretation — and that proposition supports insisting on the statutory scheduling process for any new cannabinoid. Its limits are real: the case concerned non-psychoactive hemp foods, and the 2018 Farm Bill has since rewritten the definitions it construed. The second is the tryptamine analogy from the operator's earlier brief, and it is a genuinely effective reductio. Tryptophan is an essential amino acid sold in supermarkets. It is the biosynthetic precursor of tryptamine, which is the parent of serotonin, of melatonin, and of N,N-dimethyltryptamine, a schedule I hallucinogen. Melatonin is an over-the-counter sleep aid taken by millions; sumatriptan is a prescription migraine drug; both sit on the tryptamine skeleton. If structural relationship within a chemical family were sufficient for substantial similarity, melatonin would be an analogue of DMT, and it plainly is not treated as one. The DEA's withdrawal in 2022 of a proposal to schedule five tryptamines, after researchers and industry challenged the reasoning, is consistent with the same point. The analogy does not decide the cannabinoid question, and it should not be oversold: nobody argues melatonin has DMT-like effects, so prong (ii) disposes of the melatonin case on its own and the reductio operates only on prong (i). But on prong (i) — which is where this argument is being made — it is exactly on point.

Contested — caveat. The 2022 DEA withdrawal of the five-tryptamine scheduling proposal is taken from the operator's source, which cites trade reporting; the Federal Register withdrawal notice was not located in this pass. The melatonin reductio operates on prong (i) only.

Sources: United States Court of Appeals for the Ninth Circuit 2004 · United States Code 2018 · United States Code 1986 · United States Congress 2018

What cuts against the position, part one: trace occurrence and "synthetically derived" contested in vitro

This is the strongest objection and it does not go through the Analogue Act at all, which is why winning the analogue argument does not win the case. Citti and colleagues reported THCP in the FM2 medicinal variety at the level of thousandths of a percent — figures of roughly 0.0023 to 0.0136 percent are quoted from that work. At that level, extraction from plant material is not a commercial proposition: the mass of biomass required to yield a kilogram of material is out of reach, and the economics are not close. It follows that commercial THCP is not agricultural in origin. It is produced by chemical means, and the existence of preparative routes is documented in the literature — Citti and colleagues' 2019 paper includes preparation of reference material, and the general synthetic literature on this scaffold is reviewed by Bloemendal and colleagues. This shelf does not reproduce any of that; the point here is purely legal. A compound produced by chemical means outside the plant engages the "synthetically derived tetrahydrocannabinols" language of the DEA interim final rule, and after 12 November 2026 it engages the statutory exclusion in section 781 for cannabinoids not naturally produced by the plant or synthesised outside it — and both operate regardless of whether the compound is an analogue. The Analogue Act argument is an answer to one theory of illegality. This is a different theory, it applies to the actual commercial material rather than to the molecule in the abstract, and on current agency positions it is the harder one to answer. Anyone using this brief should know that, and should not be surprised by it in a hearing.

Contested — caveat. The 0.0023 to 0.0136 percent figures come from a single 2019 study of one medicinal variety, and the denominator reported in secondary sources varies between percent of plant material and percent of total THC. Either way the level is trace. Do not generalise the number to other chemotypes.

Sources: Citti C 2019 · Citti C 2024 · Bloemendal VRLJ 2020 · Drug Enforcement Administration 2020 · United States Congress 2025 · United States Code 2018

What cuts against the position, part two: the states can make it irrelevant

A state does not need the Analogue Act and does not need to engage with any of the chemistry on this page. It can add a compound to its own controlled-substances schedule by name, in which case similarity is not in issue. It can cap total intoxicating cannabinoids, or total THC-equivalents, by a standard that is indifferent to which cannabinoid is present — and a potency-weighted or total-intoxicant standard captures a homolog automatically, by design. It can prohibit all cannabinoids other than a named permitted set, which is what Texas Senate Bill 3 would have done in 2025 before it was vetoed. It can cap milligrams per serving and per package, as Minnesota does. It can have its own analogue statute, drafted more broadly than the federal one and construed by its own courts. Several states have done several of these things. For a business, the consequence is that the federal analogue argument on this page can be entirely correct while the product is a felony in the state where it is stored, shipped or sold — and state law is where prosecutions overwhelmingly happen. A brief that only argues the federal side is not usable by the industry it is written for.

Sources: Texas Legislature 2025 · Office of the Governor of Texas (Greg Abbott) 2025 · Minnesota Statutes 2022 · United States Code 1986

Prong-by-prong assessment, stated honestly contested

Set out as an assessment rather than a conclusion, because the question is unlitigated and an honest brief says so. There is no reported decision applying 21 U.S.C. § 802(32) to THCP or to the octyl homolog. The strength ratings below are this shelf's own assessment of the argument, not a prediction and not advice.

Contested — caveat. Unlitigated. No reported decision applies the analogue definition to these compounds. The strength ratings are this shelf's assessment of an argument, not a prediction of outcome and not advice. Counsel in the relevant jurisdiction is not optional here.

Sources: United States Code 1986 · United States Code 1986 · Supreme Court of the United States 2015 · United States Court of Appeals for the Third Circuit 2003 · Citti C 2019 · Drug Enforcement Administration 2020 · United States Congress 2025